Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity

A pharmaceutical composition comprising a compound having the structure of Formula (A):

• a tautomer thereof;
• or a pharmaceutically acceptable derivative thereof;
• wherein C=C is cis or trans;
• A represents an optionally substituted aromatic or non-aromatic 5-6 membered monocyclic ring, optionally containing 1-4 heteroatoms selected from N, O or S;
• or an optionally substituted aromatic or non-aromatic 8-12 membered bicyclic ring, optionally containing 1-6 heteroatoms selected from N, O or S;
• q is one or two;
• and
• each R is independently selected from the group consisting of hydrogen, halogen, hydroxyl, —NO2, —CN, an optionally substituted aliphatic, heteroaliphatic, aromatic, heteroaromatic moiety;
• —ORR, —S(═O)nRd, —NRbRc, and —C(═O)Ra;
• wherein n is 0-2, RR is an optionally substituted aliphatic, heteroaliphatic, aromatic, heteroaromatic moiety;
• Ra, for each occurrence, is independently selected from the group consisting of hydrogen, hydroxy, optionally substituted aliphatic, heteroaliphatic, aryl and heteroaryl;
• Rb and Rc, for each occurrence, are independently selected from the group consisting of hydrogen;
• hydroxy;
• SO2Rd;
• optionally substituted aliphatic, heteroaliphatic, aryl and heteroaryl;
• Rd, for each occurrence, is independently selected from the group consisting of hydrogen;
• —N(Re)2;
• optionally substituted aliphatic, aryl and heteroaryl;
• and
• Re, for each occurrence, is independently hydrogen or optionally substituted aliphatic;
• in an aqueous buffered saline containing about 40% to about 60% (v/v) polyethylene glycol 300 and about 5% to about 15% polysorbate 80;
• wherein the compound of Formula A has HGF/SF activity.